June 25, 2008 – Global Therapeutics received CE Mark approval for a new cobalt chromium bare metal coronary stent, the GTX Coronary Stent System, which targets the bare metal stent market.
The GTX stent is reportedly engineered to eliminate the technical challenges, such as recoil, stent balloon retention and stent spring-back, that have been associated with earlier cobalt chromium stent designs currently on the market.”
According to the manufacturer, the GTX may offer a significant cost-savings. Bare metal versions of coronary stents historically cost about one-third as much as their drug-coated iterations, making bare metal stents a more cost-effective option in treating many coronary disease patients.
For more information: www.cookmedical.com
October 16, 2024 
